Amniotics: On the Way to the First Clinical Trial - Redeye
Redeye notes that Amniotics is following its plan to initiate its first clinical trial during H1 2022, after having handed in the CTA for PulmoStem in Covid-19.
ANNONS
Redeye notes that Amniotics is following its plan to initiate its first clinical trial during H1 2022, after having handed in the CTA for PulmoStem in Covid-19.